Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

IDEAYA Biosciences (30J) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Ide574, Fulvestrant InjectionNon-Small Cell Lung Cancer (Nsclc), Castration-Resistant Prostate Cancer (Crpc), Er+, Her 2- Breast Cancer, Microsatellite Stable (Mss) Colorectal Carcinomaphase1AndPhase2RecruitingA Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsApr 01, 2026
Ide034Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Head And Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Colorectal Cancer, Endometrium Cancer, High Grade Serous Ovarian Cancer, Castration-Resistant Prostate CancerPhase IRecruitingA Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesMar 19, 2026―
Ide397, Ide892Non-Small Cell Lung Cancer Nsclc, Pleural Mesothelioma, Bladder Cancer, Gastric Adenocarcinoma, Mesothelioma, Gastroesophageal Cancer (Gc), Nsclc Adenocarcinoma, Adenocarcinoma Of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (Uc), Peritoneal MesotheliomaPhase IRecruitingA Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsNov 13, 2025
Ide849Small-cell Lung Cancerphase1AndPhase2RecruitingA Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerSep 11, 2025
Darovasertib, Primary Local TherapyUveal MelanomaPhase IIIRecruitingNeoadjuvant Darovasertib in Primary Uveal MelanomaJun 03, 2025―
Gsk4418959, Pd-1 InhibitorRectal Cancer, Colon Cancer, Neoplasms, Colorectal, Solid Tumor, Endometrial Cancerphase1AndPhase2RecruitingA Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsNov 26, 2024―
Pembrolizumab, Nivolumab, Ipilimumab, Dacarbazine, Ide196, CrizotinibMetastatic Uveal Melanomaphase2AndPhase3RecruitingIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaJul 12, 2023
DarovasertibUveal MelanomaPhase IIRecruiting(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaJun 06, 2023―
Pembrolizumab, Ide-161Head And Neck Cancers, Advanced Or Metastatic Solid Tumors, Endometrial Cancer, Nsclc, Ovarian Cancer, Breast Cancer, Prostate Cancer, Colorectal CancerPhase IRecruitingA Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsMar 17, 2023―
Sacituzumab Govitecan, Paclitaxel, Docetaxel, Ide397Solid TumorPhase IRecruitingStudy of IDE397 in Participants With Solid Tumors Harboring MTAP DeletionMar 09, 2021―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Ideaya Biosciences (DE:30J) have in its pipeline
IDEAYA Biosciences DE:30J is currently developing the following drugs: Ide574, Fulvestrant Injection, Ide034, Ide397, Ide892, Ide849, Darovasertib, Primary Local Therapy, Gsk4418959, Pd-1 Inhibitor, Pembrolizumab, Nivolumab, Ipilimumab, Dacarbazine, Ide196, Crizotinib, Darovasertib, Pembrolizumab, Ide-161, Sacituzumab Govitecan, Paclitaxel, Docetaxel, Ide397, Ide196, Binimetinib, Crizotinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.